September 18, 2017 / 12:34 PM / in a month

BRIEF-Fate Therapeutics initiates Phase 2 PROTECT study of ProTmune

Sept 18 (Reuters) - Fate Therapeutics Inc

* Fate Therapeutics Inc - initiates Phase 2 protect study of protmune for prevention of acute graft-versus-host disease

* Fate Therapeutics Inc - Phase 2 stage is assessing safety and efficacy of ProTmune in 60 subjects

* Fate Therapeutics Inc - co initiated enrollment in Phase 2 stage of PROTECT, 13 U.S. centers currently open for enrollment Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below